RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Abstract Variants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients with cancer harbor RAS mutations, which are typically associated with poor clinical outcomes. Over the past four decades, KRAS has long been considered an undruggable tar...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | https://doi.org/10.1186/s13045-024-01631-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|